| Literature DB >> 29511282 |
Veronica Ferrero1,2, Elisa Fiorina1, Matteo Morrocchi3,4, Francesco Pennazio1, Guido Baroni5, Giuseppe Battistoni6, Nicola Belcari3,4, Niccolo' Camarlinghi3,4, Mario Ciocca7, Alberto Del Guerra3,4, Marco Donetti7, Simona Giordanengo1, Giuseppe Giraudo1, Vincenzo Patera8,9, Cristiana Peroni1,2, Angelo Rivetti1, Manuel Dionisio da Rocha Rolo1, Sandro Rossi7, Valeria Rosso3,4, Giancarlo Sportelli3,4, Sara Tampellini7, Francesca Valvo7, Richard Wheadon1, Piergiorgio Cerello10, Maria Giuseppina Bisogni3,4.
Abstract
Particle therapy exploits the energy deposition pattern of hadron beams. The narrow Bragg Peak at the end of range is a major advantage but range uncertainties can cause severe damage and require online verification to maximise the effectiveness in clinics. In-beam Positron Emission Tomography (PET) is a non-invasive, promising in-vivo technique, which consists in the measurement of the β+ activity induced by beam-tissue interactions during treatment, and presents the highest correlation of the measured activity distribution with the deposited dose, since it is not much influenced by biological washout. Here we report the first clinical results obtained with a state-of-the-art in-beam PET scanner, with on-the-fly reconstruction of the activity distribution during irradiation. An automated time-resolved quantitative analysis was tested on a lacrimal gland carcinoma case, monitored during two consecutive treatment sessions. The 3D activity map was reconstructed every 10 s, with an average delay between beam delivery and image availability of about 6 s. The correlation coefficient of 3D activity maps for the two sessions (above 0.9 after 120 s) and the range agreement (within 1 mm) prove the suitability of in-beam PET for online range verification during treatment, a crucial step towards adaptive strategies in particle therapy.Entities:
Mesh:
Year: 2018 PMID: 29511282 PMCID: PMC5840345 DOI: 10.1038/s41598-018-22325-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The INSIDE in-beam PET in one of the CNAO treatment rooms. The mobile support is placed between the horizontal beam line nozzle and the patient bed, ready for acquisition. The beam direction is shown in the picture.
Figure 2(a) Treatment plan and set up. Axial (left), coronal (centre) and sagittal (right) sections of the patient CT with the planned dose distribution to be delivered in the beam field monitored with the INSIDE in-beam PET system and the Clinical Target Volume (CTV) superimposed in white. (b) Time Evolution of a 2D slice of the detected beam-induced activity superimposed to the patient Computed Ttomography (CT) used for dose planning. The top and bottom rows refer to the first (December, 1st, 2016), and second (December, 2nd, 2016) acquisition days, respectively. The shown images correspond to 3D activity map reconstructions at the end of every minute, starting from the beginning of the treatment. An additional image corresponding to the whole treatment plus 30 s after-treatment is also shown. The image look-up tables refer to different intensity scales because of the different amounts of data integrated during the time intervals.
Figure 3Reconstructed activity profiles along the beam direction (z) for 1 pixel in the transverse plane (xy), at three different time intervals corresponding to one half of the delivery (120 s), the end of treatment (240 s) and the end of acquisition (270 s). The distributions are normalised to their maximum activity value.
Figure 4(a) Pearson’s Correlation Coefficient calculated for each couple of PET images, reconstructed every 10 s, as a function of time. (b) Mean difference (black) and standard deviation (white) calculated with the BEV method. (c) Mean difference (black) and standard deviation (white) calculated with the OV method.